Results 101 to 110 of about 33,638 (198)

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, Volume 183, Issue 14, Page 3970-3991, July 2026.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, Volume 183, Issue 14, Page 3897-3919, July 2026.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

The Henry reaction: spectroscopic studies of nitrile and hydroxylamine by-products formed during synthesis of psychoactive phenylalkylamines

Open Chemistry, 2008
Guy Michelle, Freeman Sally, Alder John, Brandt Simon   +3 more
doaj   +1 more source

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, Volume 183, Issue 14, Page 4058-4071, July 2026.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology

British Journal of Pharmacology, Volume 183, Issue 14, Page 4022-4047, July 2026.
Theorized mechanism of dopamine homeostasis restoration in the nucleus accumbens core induced by a psychedelic intervention. Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depression because of their ability to alter consciousness and afflicted cognitive ...
Lucas Wittenkeller, Gary Gudelsky, T. John Winhusen, Davide Amato   +3 more
wiley   +1 more source

Differential Impacts of Methadone and Buprenorphine/Naloxone on Pain‐Related Outcomes Among People With Non‐Heroin Opioid Use Disorder: Secondary Analyses From a Pragmatic Canadian Multisite Trial

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction In addition to their use as opioid agonist therapy (OAT), methadone and buprenorphine/naloxone also have analgesic properties. However, there is limited information on the relative effectiveness of these medications for analgesia in the context of treatment for non‐heroin opioid use disorder (OUD).
Katie Lyman, JinCheol Choi, Didier Jutras‐Aswad, Bernard Le Foll, Sukhpreet Klaire, M. Eugenia Socias   +5 more
wiley   +1 more source

Accuracy of Patient‐Reported Exposure to New Psychoactive Substances and Other Illicit Drugs in Australian Emergency Departments: Findings From the Emerging Drugs Network of Australia

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction New psychoactive substances (NPS) present a unique challenge in clinical, public health and drug‐policy contexts. Continued diversity, unknown potency and often unintentional exposure can limit the accuracy of self‐reported data.
Marjan J. Nijmeijer, Jennifer L. Smith, Courtney Weber, Bas W. J. Bens, Daniel M. Fatovich, Shaun L. Greene, Jennifer L. Schumann, Paul Dessauer, Rebekka Syrjanen, Katherine Z. Isoardi, Keith Harris, Sam Alfred, Viet Tran, Ewoud ter Avest   +13 more
wiley   +1 more source

Changes in THC Positivity Rates in Adolescents Corresponding to Legalization of Recreational Marijuana in Illinois. [PDF]

West J Emerg Med
Gassé E, Brill A.
europepmc   +1 more source

Payday Loan Use Among People With Lived and Living Experience of Substance Use

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction Due to high‐penalty lending practices, short‐term, small‐dollar payday loans can trap borrowers in cycles of debt and reinforce socioeconomic disadvantage. People with lived and living experience of substance use (PWLLE) who often contend with financial and labour market exclusion and have relatively inflexible cash flow needs may
Allison Laing, Kanna Hayashi, Michael John Milloy, Thomas Kerr, Lindsey Richardson   +4 more
wiley   +1 more source

Prescription stimulant consumption in the United States compared with 35 other countries. [PDF]

Health Aff Sch
Bachhuber MA, Jordan AE, Piper BJ.
europepmc   +1 more source